The U.S. Air Force dispatched a nuclear sniffer plane today to the Sea of Japan, which is east of the Korean Peninsula.
“The WC-135 Constant Phoenix, a special-purpose U.S. plane, made an emergency sortie today over the East Sea,” an anonymous source told the Korean news outlet Yonhap this morning.
WC-135 Constant Phoenix sniffer plane, Oct. 10, 2006.
WC-135 Constant Phoenix sniffer plane, Oct. 10, 2006.Today’s flight “appears meant to check whether the secretive Communist nation [of North Korea] has detonated a nuclear bomb,” Yonhap explained.
stock market technical analysis: Bayer Aktiengesellschaft (BAYZF)
Advisors’ Opinion:
- [By SEEKINGALPHA.COM]
Other R&D products in Regeneron’s pipeline that we are interested in
Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.
Click to enlarge
- [By SEEKINGALPHA.COM]
And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.
- [By SEEKINGALPHA.COM]
We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.
- [By SEEKINGALPHA.COM]
Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.
In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.
Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu
stock market technical analysis: Ligand Pharmaceuticals Incorporated(LGND)
Advisors’ Opinion:
- [By Keith Speights]
Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).
- [By Keith Speights, Sean Williams, and Cory Renauer]
So when we asked three of our top healthcare contributors to name three of the best stocks to invest in healthcare, it’s not surprising that their responses listed companies in three different industries: medical device makerMasimo (NASDAQ:MASI), pharmacy services giant CVS Health (NYSE:CVS) and biopharmaceutical company Ligand Pharmaceuticals (NASDAQ:LGND). Here’s why these three healthcare stocks stand out as smart picks.
stock market technical analysis: Occidental Petroleum Corporation(OXY)
Advisors’ Opinion:
- [By Michael Flannelly]
Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.
Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.
Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”
Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.
- [By Ben Levisohn]
We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…
- [By Lee Jackson]
These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).
- [By Garrett Cook]
Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.
- [By Paul Ausick]
Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.
- [By Ben Levisohn]
Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).
stock market technical analysis: Fiat Chrysler Automobiles N.V.(FCAU)
Advisors’ Opinion:
- [By Douglas A. McIntyre]
After several blows to its quality reputation from major research firms like Consumer Reports and J.D. Power, Fiat Chrysler Automobiles N.V. (NYSE: FCAU) has been let down by its dealers. In the new J.D. Power 2017 U.S. Customer Service Index (CSI) Study, the manufacturer’s Fiat, Jeep, Ram and Dodge took the bottom four spots. The company’s Chrysler brand ranked almost as poorly.
- [By Douglas A. McIntyre]
Image a car company with sales off 19% through the first 11 months of the year. Imagine a car company that routinely ranks at or near the bottom of the evaluations of Consumer Reports, J.D. Power rankings and the American Customer Satisfaction Index. Imagine a car company that routinely has 100 days of vehicle in inventory, compared to an industry average near70. That company isFiat, the small car division of Fiat Chrysler Automobiles N.V. (NYSE: FCAU).
- [By John Rosevear]
The fifth-generation version of Honda’s well-regarded kid-hauler doesn’t look a whole lot different from the outgoing model, but it packs a slew of upgradesand some useful technology that Honda hopes will make it more competitive with fierce rivals from Toyota (NYSE:TM) and Fiat Chrysler Automobiles (NYSE:FCAU).
- [By Jeremy Bowman]
As for individual stocks, Fiat Chrysler(NYSE:FCAU) shares dove 10.3% after the EPA accused the automaker of cheating on emissions tests, similar to the way Volkswagendid. Elsewhere,Hess(NYSE:HES) shares dropped 4.8% after the oil company revealed $4.6 billion in charges for Q4 2016.
